Krystal Biotech Reports Strong Q1 on VYJUVEK, Readies Wider Launches
Strong profits paired with a large cash reserve signal capacity to fund expansion.
Overview
- Krystal Biotech posted Q1 net revenue of $116.4 million from VYJUVEK, up 9% from the prior quarter and 32% year over year.
- Profitability stayed high with a 95% gross margin and $55.9 million in net income, marking an 11th straight quarter of positive earnings per share.
- U.S. sales reached $87.5 million, and management said insurance plan changes and start‑stop maintenance dosing can create normal quarter‑to‑quarter swings.
- International markets contributed $28.9 million as the company prepares VYJUVEK launches in Italy and Spain in the second half of 2026 and continues price talks in Germany and France.
- Two registrational readouts are slated for 2026 covering KB801 for neurotrophic keratitis and KB803 for corneal disease in DEB, with other programs progressing.